Delving into the Latest Updates on Dimetindene Maleate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Dimethindene, Dimethindene maleate (USAN), Dimetindene maleate (JAN)

+ [7]

Target

H1 receptor

Mechanism

H1 receptor antagonists(Histamine H1 receptor antagonists)

Therapeutic Areas

Immune System DiseasesSkin and Musculoskeletal Diseases

Active Indication

HypersensitivityPruritus

Inactive Indication-

Originator Organization-

Active Organization-

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC20H24N2

InChIKeyMVMQESMQSYOVGV-UHFFFAOYSA-N

CAS Registry5636-83-9

View All Structures (2)

AbstractDimetindene is a sedating antihistamine indicated for the symptomatic treatment of allergic conditions. Dimetindene is marketed among others under the trade name Fenistil (oral solution). Toxicity data are limited, and there is no consensus on the dose at which children require hospitalization. Objective is to determine the potentially toxic dose in children. Data in children with age up to 15 years were obtained from hospital discharge reports. Of 139 paediatric hospital discharge reports, 23 cases (16.5%) were excluded because of uncertain ingestion. In 116 children (46 boys and 70 girls, mean age 2 years and 9 months ± 1 year and 1 month), the majority of children developed no symptoms (87 children, 75%, mean age 3 years±1 year) and the remaining 29 children (25%, mean age 2 years and 11 months ± 1 year and 3 months) developed only mild and spontaneously resolving symptoms of poisoning after a dose of 0.82 ± 0.32 mg/kg b.w. (range 0.26–1.82 mg/kg). In 98% of all cases, hospitalized children were observed for a maximum 24 h, and their condition did not require specific treatment. In conclusion, the prognosis for accidental dimetindene poisoning in children appears to be good and the minimum toxic dose has been determined to be 0.5 mg/kg b.w.

01 Apr 2024·European Journal of Neurology

Icatibant averting mechanical ventilation in acute ischemic stroke patient with alteplase‐induced orolingual angioedema

Article

Author: Vassilopoulou, Sofia ; Chondrogianni, Maria ; Palaiodimou, Lina ; Tzanetakos, Dimitrios ; Keramida, Anna ; Makris, Michael ; Theodorou, Aikaterini ; Bakola, Eleni ; Dimitriadou, Evangelia-Makrina ; Tsivgoulis, Georgios ; Paraskevas, Georgios P

AbstractBackground and purposeOrolingual angioedema (OA) represents a rare but life‐threatening complication among patients with acute ischemic stroke treated with intravenous thrombolysis with alteplase. Novel agents, including icatibant, are recommended in resistant patients with alteplase‐induced OA who have failed to respond to first‐line therapies including corticosteroids, antihistamines, and/or adrenaline.MethodsWe present a patient with alteplase‐induced OA who showed substantial clinical improvement following the administration of icatibant.ResultsWe describe a 71‐year‐old woman with known arterial hypertension under treatment with angiotensin‐converting enzyme inhibitor, who presented with acute ischemic stroke in the territory of the right middle cerebral artery and received intravenous alteplase. During intravenous thrombolysis, the case was complicated with OA without any response to standard anaphylactic treatment including corticosteroids, dimetindene, and adrenaline. Thirty minutes after symptom onset, icatibant, a synthetic selective bradykinin B2‐receptor antagonist, was administered subcutaneously. Substantial symptomatic resolution was observed only following the icatibant administration.ConclusionsThis case highlights the effectiveness of icatibant in the acute management of alteplase‐induced OA. In particular, icatibant administration, following first‐line therapies including corticosteroids, antihistamines, and/or adrenaline, may avert tracheostomy and intubation in resistant and refractory cases with OA following intravenous thrombolysis for acute ischemic stroke.

1

News (Medical) associated with Dimetindene Maleate

14 Nov 2024

·www.adalvo.com

Adalvo announces successful DCP Submission for Ivermectin topical cream

Adalvo is pleased to announce the successful EU DCP Submission for Ivermectin 10mg/g topical cream. Our Ivermectin cream is being developed in collaboration with one of our strategic partners, based on the reference brand Soolantra, Galderma. The product is used on the skin to treat pimples and spots found with rosacea. According to IQVIA, the INN with strength 1%(10mg/g) generated approximately $214mn in global sales in 2022. With our clearly defined product pathway, we believe Adalvo will be amongst the first wave of filers, and will be ready to launch on Day-1 in all major markets. As a company committed to our dermatology portfolio, we offer an array of dossiers and aim to assist our partners in overcoming any challenges that may arise with these mature products. Our dermatology products include: Adapalene Gel Adapalene + Benzoyl Peroxide Gel Tacrolimus Ointment Dimetindene Gel

100 Deals associated with Dimetindene Maleate

Login to view more data